Effects of early intracoronary streptokinase on infarct size estimated from cumulative enzyme release and on enzyme release rate: A randomized trial of 533 patients with acute myocardial infarction*

The effects of early intracoronary streptokinase (SK) on enzymatic infarct size and rate of enzyme release were studied in a randomized multicenter trial. A total of 533 patients with acute myocardial infarction (AMI) were allocated to either the SK treatment group (n = 269) or the conventional (control) treatment group (n = 264). Enzymatic infarct size was represented by the cumulative quantity of α-hydroxybutyrate dehydrogenase (HBDH) released by the heart per liter of plasma in the first 72 hours. Rate of enzyme release was represented by the ratio of HBDH quantities released in 24 hours and 72 hours. On an “intention to treat” basis, the SK group had a smaller (by 30%; p = 0.0001) median enzymatic infarct size and a higher (by 35%; p = 0.0001) median rate of enzyme release than the control group. Limitation of infarct size was less apparent in patients treated with intracoronary SK only (25%) than in patients treated with intravenous plus intracoronary SK (34%). Compared to the control group, the enzyme release rate in patients treated with intracoronary SK only was slightly less (34%) than that in patients treated with intravenous plus intracoronary SK (38%). Patients with a patent infarct-related coronary artery at acute angiography had a median infarct size which was 25% (p = 0.0001) smaller than the median infarct size of the control group, and the median rate of enzyme release was 28% (p = 0.001) higher than the median release rate of the control group. Patients with successful recanalization during intracoronary SK infusion had a median infarct size which was 31% (p = 0.002) smaller than the median infarct size of the control group and a median rate of enzyme release which was 42% (p = 0.0001) higher than the median release rate of the control group. Patients with persistent coronary occlusion in spite of thrombolytic therapy had a median infarct size which was 11% (NS) higher than the median infarct size of the control group, although the median rate of enzyme release was still 23% (p = 0.02) higher than the median release rate of the control group. It is concluded that thrombolysis in the early phase of AMI limits infarct size and that intracoronary SK treatment itself accelerates the process of enzyme release from infarcted myocardium, independent of the angiographic result. (Am Heart J 1986;112:672.)


Working group on thrombolytic therapy in acute myocardial infarction of the Netherlands Interuniversity Cardiology Institute.

*Participating centers and collaborators: Thoraxcenter, Erasmus University Hospital Dijkzigt, Rotterdam (M v/d Brand, P de Feyter, P Fioretti, P G Hugenbolz, P W Serruys, M L Simoons, W Wijns); Department of Cardiology, Free University, Amsterdam (M van Renige, J Res, J Roux, F Visser, F W A Verheugt, E E v/d Wall); Department of Cardiology, Twenthe, Rotterdam (D van Hoogenhuyze, X H Krauss, W J Remme, C J Storm, H A C M Kruysen); Department of Cardiology, St Annaal Hospital, Maastricht (F Bär, S Kraus, P Brugada, K den Dulk, W T Hermens, M Ramunzel, H J J Wellens, G M Willems, C de Zwaan); Department of Cardiology, University Hospital, Leiden (B Buin, J Engbers, A v/d Laarse); Data processing center, Thoraxcenter, Erasmus University Rotterdam (S v/d Does, R van Domburg, J Lubsen, J P van Mantgem, K de Neef, J Planellas, F Vermeer, A Wagenaar, I Zorn).
Both short- and long-term prognosis of patients who have had a myocardial infarction depends largely on "infarct size," or rather on the remaining functioning myocardial tissue. Thus it is likely that limitation of "infarct size" will lead to a better prognosis of infarct patients. Early recanalization of the occluded coronary artery in patients with acute myocardial infarction (AMI) has been proposed as a method for myocardial salvage. We recently completed a study of 533 patients comparing early recanalization by intracoronary administration of streptokinase (SK) with conventional treatment. The results indicate that early recanalization does indeed limit "infarct size" (estimated from serial enzyme determinations), thereby preserving myocardial function (estimated by contrast angiography and radionuclide angiography). Finally, the 1-year survival rate in patients allocated to thrombolytic therapy was significantly improved compared to that of patients in the control group (91% vs 84%).

This report further details the effects of thrombolytic therapy on the estimated "infarct size" by calculation of total $\alpha$-hydroxybutyrate dehydrogenase (HBDH) enzyme release and the effects of treatment on the rate of enzyme release. Limitation of infarct size was only apparent in patients with a patent infarct-related artery after the intervention. However, in contrast with earlier reports, the rate of enzyme release appeared to be accelerated by thrombolytic therapy independent of the angiographic results.

**METHODS**

**Patient selection.** The study, sponsored by the Netherlands Interuniversity Cardiology Institute, was initiated in one hospital in 1981 and later extended to five hospitals. All patients admitted to the participating coronary care units were eligible for the trial if severe chest pain lasting more than 20 minutes was accompanied by ST segment elevation of 0.2 mV or greater in one or more precordial leads and/or 0.1 mV or greater in one or more limb leads. In addition, patients were included who had 0.2 mV ST segment depression in precordial leads indicative of posterior wall infarction. Patients up to the age of 70 years were included if they were admitted to the coronary care unit within four hours after the onset of symptoms. Exclusion criteria were: previous treatment with SK, bypass surgery of the infarct-related vessel, recent trauma, traumatic resuscitation, gastrointestinal bleeding, gastric or duodenal ulcer, hemorrhage or cerebrovascular accident within 3 months, pregnancy or menstruation, or inability to give informed consent.

Eligible patients were registered by a telephone answering service which then provided treatment allocation. After randomization, informed consent was requested from patients allocated to the group receiving thrombolytic therapy only. Prior to cardiac catheterization patients received nitroglycerin, lidocaine (2 mg/min), heparin (5000 U), acetylsalicylic acid (250 mg), and prednisolone (100 mg) intravenously. Coronary arteriography was performed with preformed catheters from the femoral approach. If the infarct-related artery appeared occluded, SK was administered intravenously at the rate of 4000 U/min until all visible clots disappeared. Usually 250,000 U was given. In patients with persistent occlusion, selective infusion or mechanical perforation of the thrombus was attempted on occasion, while percutaneous transluminal coronary angioplasty was performed in some of the patients with severe residual stenosis of the infarct-related coronary artery. In order to reduce treatment delay, in patients admitted since January, 1984, 500,000 U of SK was administered intravenously, immediately after informed consent was obtained, as soon as possible, followed by intracoronary SK infusion during acute cardiac catheterization.

**Measurement of serum enzyme activities.** Samples of 5 ml of venous blood were obtained at admission, directly after the SK infusion procedure (if allocated to study treatment), every 12 hours for the first 2 days, and daily for the following 3 days. The blood samples were allowed to clot, and the activities of HBDH in the serum were measured in the coronary care units of Rotterdam Thoraxcenter, Maastricht St. Annadal Hospital, and the University Hospital Leiden, and the activity of lactate dehydrogenase (LDH) in the serum was measured in the Rotterdam Zuidzrizerkenhuis and the Amsterdam Free University Hospital. Because erythrocytes contain high activity levels of LDH-1 and LDH-2, hemolytic samples were discarded, and new samples were ordered. Activity levels are expressed in micromoles of $\alpha$-ketobutyrate converted (HBDH) or micromoles of pyruvate converted (LDH) per minute or liter of serum at 37ºC. The autoanalyzers which measured HBDH activities were calibrated daily such that the HBDH activity of a test serum (Autonorm H, batch 227, Nyegaard & Co, Oslo, Norway) equaled 430 U/L. So calibrated, the mean reference value of HBDH activity in serum is 83 U/L. From the autoanalyzers, which measured LDH activities, the serum LDH activities were converted to HBDH activities via the following formulas: Amsterdam Free University Hospital HBDH = 1.106 × LDH + 16 ($r = 0.96$), and Rotterdam Zuidzrizerkenhuis HBDH = 0.473 × LDH - 5 ($r = 0.99$). These formulas were obtained after LDH and HBDH measurement of 10 dilutions of an infarct serum diluted with a pasteurized plasma protein solution (Central Laboratory of the Netherlands Red Cross Blood Transfusion Service, Amsterdam, the Netherlands) spanning an LDH range of 0 to 2000 U/L.

**Calculation of cumulative HBDH release.** Previously the two-compartment model was presented with which the movements of liberated myocardial proteins to and from intravascular and extravascular spaces can be described. This model has now been verified for a great number of proteins, mostly enzymes. Briefly, this model...
Table I. Median values (M) and first and third quartiles (Q₁,Q₃) of calculated and estimated cumulative HBDH release of patients allocated to thrombolytic therapy and to conventional treatment (control subjects) groups

<table>
<thead>
<tr>
<th>Patients</th>
<th>Streptokinase</th>
<th>Control</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>n</td>
<td>M</td>
</tr>
<tr>
<td>448 patients with HBDHQ72 calculated†</td>
<td>230</td>
<td>770</td>
</tr>
<tr>
<td>495 patients with HBDHQ72 calculated</td>
<td>248</td>
<td>770</td>
</tr>
<tr>
<td>(448) or estimated including 17 patients without AMI (Q72 = 40 U/L) and 30 patients who died early (8 SK, 22 control, Q72 = 6000 U/L)†</td>
<td>1.2 × Q₄₈</td>
<td></td>
</tr>
<tr>
<td>29 patients with Q72 estimated by</td>
<td>14</td>
<td>860</td>
</tr>
<tr>
<td>1.2 × Q₄₈</td>
<td>9 patients with Q72 estimated from CK(MB) curves</td>
<td>7</td>
</tr>
<tr>
<td>All 533 patients with Q72§</td>
<td>269</td>
<td>790</td>
</tr>
</tbody>
</table>

*Mann-Whitney test.
†Indicated by HBDHQ72.
‡Indicated by HBDHQ72A.
§Indicated by HBDHQ72B.
AMI = acute myocardial infarction.

enables the calculation of the total quantity of enzyme which has entered the plasma up to time \( t \) (\( Q(t) \)) per liter of plasma. If the release of enzymes into plasma starts at time \( t = 0 \), \( Q(t) \) equals the quantity of enzyme present in 1 L of plasma (\( C(t) \)) plus the quantity of enzyme present in the extravascular compartment per liter of plasma (\( C'(t) \)) plus the quantity of enzyme that has been eliminated from 1 L of plasma up to time \( t \). Cumulative release of enzyme per liter of plasma up to time \( t \), \( Q(t) \), is represented by:

\[
Q(t) = C'(t) + C(t) + FCR \int_{0}^{t} C'(r)dr \quad \text{(equation 1)}
\]

in which FCR is the fractional catabolic rate constant, and \( C'(t) \) and \( C(t) \) are the enzyme concentrations at time \( t \) in plasma and the extravascular space, respectively. The accents added to \( C'(t) \) and \( C(t) \) in equation 1 indicate that enzyme concentrations are corrected for the normal steady-state concentration \( C_0 \), that is, \( C'(t) = C(t) - C_0 \).

This implies that \( Q(t) \) does not include normal steady-state release of enzyme but only refers to the extra release of enzyme resulting from AMI. The term \( C'(t) \) can be calculated according to the formula: \( C'(t) = \text{TER} × e^{-\text{ERR} t} \int_{0}^{t} e^{-\text{ERR} r} C'(r)dr \quad \text{(equation 2)} \)

in which \( \text{TER} \) and \( \text{ERR} \) represent the transcapillary escape rate constant and the extravascular return rate constant, respectively.\(^{19}\) With the use of fixed mean values for FCR, \( \text{TER} \), and \( \text{ERR} \) being 0.015 hr⁻¹, 0.014 hr⁻¹, and 0.018 hr⁻¹, respectively, \( Q(t) \) was calculated from serial determinations of serum HBDH activities and the normal steady-state HBDH activity \( C_0 = 83 \text{ U/L} \). The total HBDH activity ultimately released by the infarcted myocardium is represented by HBDHQ72 as at 72 hours after onset of chest pain enzyme release rate is almost (≥ 95%) completed by then.\(^{16}\)

**Calculation of HBDH release rate.** As a measure of the rate with which enzymes are liberated from the myocardium into the circulation, the ratio HBDHQ24/HBDHQ72 is used, that is, the ratio of the quantities released in the first 24 hours and the first 72 hours.

**Statistical analysis.** Differences between medians of two groups of data were tested with the Mann-Whitney rank-sum test. Differences with \( p \) values >0.05 (two-sided) were considered not significant.

**RESULTS**

Between June, 1981, and March, 1985, a total of 533 patients were entered into the study. Two hundred sixty-four patients were allocated to the conventional treatment group and 269 patients to the thrombolytic therapy group. In spite of treatment allocation, no angiography was performed in 35 patients.\(^7\) In 111 of 136 patients catheterized without intravenous SK the infarct-related vessel was occluded (82%) and recanalization was achieved in 79% of these. After prior intravenous SK the infarct-related vessel was patent in 40 of 98 patients (41%). Ultimately the infarct-related artery was patent at admission or recanalized in 198 patients (85%). The median time between onset of symptoms and angiographic documentation of a patent infarct-related vessel was 200 minutes.

Of 533 patients included in the study, measurements of HBDH (or LDH) were complete in 448 patients (84%). The measurements were incomplete in 85 patients. In order to verify whether the results
would be affected by missing data, HBDHQ72 was estimated from other data which were available for these 85 patients. Data were missing from 17 patients who did not develop an infarct in spite of prolonged chest pain and significant ST segment elevation at admission. In these 17 patients creatine kinase (CK), CK-MB, HBDH, and other enzymes remained within reference ranges. Furthermore, data were necessarily incomplete in 30 patients who died early (within 72 hours) from large infarctions, characterized by pulmonary edema, cardiogenic shock, and a rapid rise of plasma enzymes to high levels. In the present analysis these patients were entered with values for HBDHQ72 which were arbitrarily set at 40 (for patients without infarct) and 6000 (for patients who died within 72 hours), respectively. The figures 40 and 6000 U/L corresponded to the lowest and the highest values of the 448 calculated infarct sizes. In 29 patients inadequate blood sampling prevented direct calculation of infarct size; however, HBDHQ72 could be approximated by multiplication of calculated HBDHQ48 by a factor of 1.2. This factor 1.2 was chosen because it was the value of the HBDHQ72/HBDHQ48 ratio in 218 control patients. Although in the patients allocated to the thrombolytic therapy group the mean ratio of HBDHQ72/HBDHQ48 was about 1.1, the factor 1.2 was used in all 29 patients in whom HBDHQ48 was present and HBDHQ72 was absent. Thus probably a small overestimation of infarct size was introduced in 14 patients allocated to the SK treatment group. In the nine patients in whom HBDHQ48 could not be calculated, HBDHQ72 was estimated via comparison of serum CK(MB) curves with serum CK(MB) curves of patients with calculated HBDHQ72.

The data presented in Table I show that the median infarct size estimated from HBDHQ72 was 25% lower in patients allocated to thrombolysis than in control patients. This difference in HBDHQ72 was hardly affected by the addition of the estimated data to the actual measurements; in fact, inclusion of estimated infarct sizes (HBDHQ72A and HBDHQ72B) increased these differences to 30% and 33%, respectively. These differences were similar among the five participating hospitals. Further analysis is based on both actual HBDH measurements (448 patients; HBDHQ72) and on data including patients without infarction and those who died early (495 patients; HBDHQ72A). Although much attention has been paid to the standardization of serum enzyme determinations, it appears that median HBDHQ72 values varied per center. This was true for both patient groups (SK and control). Fig. 1 shows the median HBDHQ72A values in both patient groups per center. Although an interdepartment variation is obvious, each center shows an almost identical result in terms of infarct size limitations of about 30%.

Table II shows the medians and quartiles of calculated HBDH release (HBDHQ) after 24, 48, and 72 hours from the onset of infarction in patients in the control and SK groups. Evidently, after 24 hours median HBDHQ values in both patient groups are almost identical, while cumulative HBDH release increases less during the following 2 days in the SK group than in the control group. At 72 hours from the onset of infarction, the median HBDHQ72 value of the SK group is 25% less than that of the control group (p = 0.0001). The difference in the time course of HBDH release between the two groups of patients is the result of a faster release of HBDH in the SK group than in the control group, as is reflected by the median HBDHQ24/HBDHQ72 which is 0.65 and 0.48 in the SK and control group, respectively (p = 0.0001).

Table III shows that median HBDHQ72A values differ by 25% in favor of SK in the first 277 patients and by 34% in favor of SK in patients pretreated with intravenous SK. The HBDH release rate was 34% and 38% higher in the SK group than in the control group for intracoronary SK and intravenous plus intracoronary SK treatment, respectively.

Fig. 2 shows the median values as well as the first and third quartile values of HBDHQ72A and ratio HBDHQ24/HBDHQ72 in patients in the control.
and SK groups. In addition, the SK group is subdivided into four groups of patients: those without catheterization (35 patients), 65 with a patent infarct-related coronary artery at angiography, 133 patients with actual recanalization by thrombolytic therapy, and 36 patients in whom the artery remained occluded (Fig. 2).

Median infarct sizes of the patients without acute coronary angiography (910 U/L), as well as those of the patients in whom the infarct-related artery remained occluded (1220 U/L), were not significantly different from those of control patients (1100 U/L). In patients with recanalization during angiography median infarct size was 760 U/L, which is 31% lower than in control patients ($p = 0.0001$). The smallest infarcts were observed in 65 patients who already had a patent infarct-related artery at first angiography (median 500 U/L). In Fig. 2 the values of the ratio HBDHQ24/HBDHQ72 are presented, which are a measure of the rate of enzyme release. The control group and the patients in the SK group who did not undergo acute coronary angiography had a relatively low median ratio HBDHQ24/HBDHQ72 (0.48 and 0.55, respectively) compared to patients with patent infarct-related coronary arteries (0.66), those with recanalization during angiography (0.68), and those with persistent occlusion (0.59).

In order to study whether the severity of the remaining stenosis of the infarct-related artery had any effect on infarct size or rate of enzyme release, patients were subdivided according to the visual interpretation of the degree of stenosis after recanalization. The results in Fig. 2 show no effect of the degree of opening of the infarct-related artery on infarct size.

Fig. 3 shows that in both anterior (including anteroseptal infarcts) and inferior (including posterior) infarcts cumulative HBDH release was lower and HBDH release rate was higher in patients allocated to SK treatment compared to control patients. When both groups are compared, median values of HBDHQ72A differ by 34% ($p = 0.007$) and by 31% ($p = 0.002$) for patients with anterior and

---

**Table II.** Median values (M) and first and third quartiles (Q1,Q3) of cumulative quantities of HBDH released per liter of plasma after 24, 48, 72, and 96 hours in patients allocated to thrombolytic therapy and to conventional treatment (control subjects) groups.

<table>
<thead>
<tr>
<th></th>
<th>Streptokinase</th>
<th>Controls</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>n  M  Q1  Q3</td>
<td>n  M  Q1  Q3</td>
</tr>
<tr>
<td>HBDHQ24</td>
<td>252 460 260 780</td>
<td>236 490 300 730</td>
</tr>
<tr>
<td>HBDHQ48</td>
<td>245 680 420 1070</td>
<td>224 920 530 1390</td>
</tr>
<tr>
<td>HBDHQ72</td>
<td>230 770 450 1330</td>
<td>218 480 580 1650</td>
</tr>
<tr>
<td>HBDHQ96</td>
<td>187 780 450 1280</td>
<td>171 900 620 1750</td>
</tr>
<tr>
<td>HBDHQ24/HBDHQ72</td>
<td>220 65 0.55 0.76</td>
<td>218 0.48 0.39 0.58</td>
</tr>
</tbody>
</table>

NS = not significant.

*Mann-Whitney rank-sum test (two-sided).

**Table III.** Median values (M) and first and third quartiles (Q1,Q3) of enzymatic infarct size (HBDHQ72A) and enzyme release rate (HBDHQ24/HBDHQ72) in patients allocated to thrombolytic therapy and to conventional treatment (control subjects)*.

<table>
<thead>
<tr>
<th></th>
<th>Streptokinase</th>
<th>Control</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>n  M  Q1  Q3</td>
<td>n  M  Q1  Q3</td>
</tr>
<tr>
<td>All patients</td>
<td>248 770 410 1260</td>
<td>247 1100 580 1860</td>
</tr>
<tr>
<td>Intracoronary SK</td>
<td>140 750 380 1220</td>
<td>137 1000 580 1700</td>
</tr>
<tr>
<td>Intravenous + intracoronary SK</td>
<td>108 810 450 1320</td>
<td>110 1220 640 2010</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th>Streptokinase</th>
<th>Control</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>n  M  Q1  Q3</td>
<td>n  M  Q1  Q3</td>
</tr>
<tr>
<td>All patients</td>
<td>230 0.65 0.55 0.76</td>
<td>218 0.48 0.39 0.58</td>
</tr>
<tr>
<td>Intracoronary SK</td>
<td>127 0.67 0.57 0.76</td>
<td>121 0.50 0.39 0.61</td>
</tr>
<tr>
<td>Intravenous + intracoronary SK</td>
<td>103 0.65 0.53 0.76</td>
<td>97 0.47 0.40 0.54</td>
</tr>
</tbody>
</table>

*Until 1984, SK was given intracoronarily only, and from January, 1984, on SK was given intravenously followed by intracoronarily.

†Mann-Whitney rank-sum test (two-sided).
inferior infarcts, respectively. Median values of the HBDHQ24/HBDHQ72 ratio differ by 31% ($p = 0.0001$) and 38% ($p = 0.0001$) for patients with anterior and inferior infarcts, respectively.

From a total of 533 patients randomized in the study, 65 (12%) patients have died within 1 year after onset of chest pain: 23 patients allocated to thrombolytic therapy and 42 control patients ($p = 0.01$). In Fig. 4 the number of patients from both groups in four classes of infarct size (HBDHQ72A ≤ 600 U/L, 601 to 1200 U/L, 1201 to 1800 U/L, and >1800 U/L) and the number of patients who have died within 1 year after onset of chest pain and per infarct size class per group are shown. This figure demonstrates that thrombolytic therapy is associated with both limitation of infarct size and an improved survival rate when compared to control patients.

Of the 264 control patients and 269 patients allocated to the SK treatment group, angiographic data before discharge from the hospital were obtained from 125 and 129 patients with first AMI, respectively. Fig. 5 shows that in the SK group the median HBDHQ72 was 800 U/L, which was 33% lower ($p = 0.0001$) than that in the control group (1190 U/L). Furthermore, in the SK group median
left ventricular ejection fraction at discharge was 0.57, which was 14% higher ($p = 0.0005$) than that in the control group (0.50).

DISCUSSION

The aim of thrombolytic therapy is rapid restoration of blood flow to the jeopardized myocardium in order to preserve cellular integrity and function or, in other words, "limitation of infarct size." Thus thrombolytic therapy must either prevent the infarction or lead to an infarct with a size smaller than would occur in the absence of thrombolysis-induced reperfusion of the infarct-related coronary artery.

Indirectly, limitation of infarct size by early intracoronary SK infusion has been demonstrated to occur since regional and global left ventricular function as well as the mortality rate were markedly improved in treated patients compared to conventionally treated patients. However, studies designed to investigate direct effects of thrombolytic therapy in terms of infarct size limitation are scarce. Therefore, in the study on thrombolytic therapy conducted by the Netherlands Interuniversity Cardiology Institute, measurement of enzymatic infarct size was incorporated. In 495 of 533 patients (93%) enrolled in the study quantitative information on infarct size (HBDH72A) was obtained. This study demonstrates that early thrombolysis does limit infarct size estimated by myocardial HBDH release. As expected, the smallest median HBDH infarct size was observed in patients with an open artery at angiography and, to a lesser extent, in patients with an occluded artery which later recanalized. Patients with a persistent occlusion in spite of thrombolytic therapy had the same infarct size as patients in the control group.

The method used to calculate infarct size in the present study is applicable to several cytoplasmic enzymes liberated from infarcted myocardium. Based on the assumption that different cytoplasmic (iso) enzymes are liberated from necrotic myocytes simultaneously, the different serum (iso)enzyme curves can be fully described by differences in their concentrations in normal myocytes and differences in fractional catabolic rate. Calculation of cumulative released quantities of these (iso)enzymes results in identical overlapping curves when activities are expressed in gram equivalents of myocardium. Thus the different cytoplasmic (iso)enzymes are released to the same extent percentage from the infarcted tissue. In infarcted animal hearts and in infarcted human hearts the extent to which the infarcted myocardium loses its enzymes is approximately 80% to 85%.

The two-compartment model employed enables calculation of the cumulative activity released from the infarcted myocardium into the plasma space for each cytoplasmic (iso)enzyme. The method has proved its value for assessing myocardial damage induced by surgical and cardioplegic procedures and for assessing the relationship between enzymat-
ic infarct size and the occurrence of pump failure, ECG changes, conduction and rhythm disturbances, global left ventricular function, wall motion abnormalities, and 1-year survival rate.\textsuperscript{17} Shell et al.\textsuperscript{29} in 1971, published a different method for calculating enzymatic infarct size, which has since then been used by a large number of investigators. This method is confined to CK and CK-MB, and is based on a one-compartment model. As in the early reports they mention a recovery rate of 30\% of the CK (or CK-MB) activity,\textsuperscript{29} and since 1975 only 15\%,\textsuperscript{31} the cumulative CK(-MB) activity calculated on the basis of serial serum CK(-MB) activities has to be multiplied by 1/0.3 (early) or by 1/0.15 (since 1975) to obtain the activity of CK(-MB) released by the heart. The remaining part of the released CK(-MB) is degraded locally in the heart according to the authors.\textsuperscript{29} The factor representing recovery of CK liberated by necrotic myocytes in the circulation appears to be sensitive to the occurrence of reperfusion of infarcted myocardium. Roberts and Ishikawa\textsuperscript{33} showed that two different relationships exist between accumulated CK release expressed in CK gram-equivalents of infarcted myocardium and anatomic infarct size during unperfused infarction and during infarction followed by early reperfusion. From reperfused myocardium greater CK release per gram of anatomic infarct size has been observed than from unreperfused myocardium.

Tamaki et al.,\textsuperscript{34} who also used the method of Shell et al.,\textsuperscript{30} observed that in patients with AMI successfully treated with intracoronary urokinase more CK-MB was released per equivalent infarct volume estimated by myocardial emission tomography with thallium-201 than in patients with AMI with unsuccessful thrombolysis. The discrepancies mentioned by these authors may reflect different recovery fractions of the enzyme in both situations, since CK as well as CK-MB are relatively unstable (iso) enzymes compared to aspartate aminotransferase and LDH (see also reference 25). However, the infarct size calculated by the method of Shell et al.,\textsuperscript{30} in patients with AMI correlated well with anatomic infarct size in patients who died from AMI,\textsuperscript{35} left ventricular ejection fraction in patients with first AMI,\textsuperscript{36,37} and long-term survival rates.\textsuperscript{14,56} Erhardt\textsuperscript{26} reported that in 43 patients with AMI the peak serum levels of LDH and heat-stable LDH (representing the combined activities of LDH-1 and LDH-2) were well correlated ($r = 0.73$ and $r = 0.79$, respectively) with anatomic infarct size, measured at postmortem examination. Anderson et al.,\textsuperscript{13} who measured serial activities of several (iso)enzymes in serum, calculated the integrated concentrations of serum LDH and serum LDH-1, and did not find significant differences between the SK group and the control group. However, recalculation of released quantities of LDH and LDH-1, by means of the method used in the present study, yielded a smaller infarct size after thrombolysis of 20\% and 40\% with LDH and with LDH-1, respectively. This is in agreement with the better left ventricular ejection fraction after thrombolysis reported by Anderson et al.\textsuperscript{13} Enzyme release rates ($Q_{24}/Q_{72}$) were 0.49 and 0.77 measured with LDH and 0.46 and 0.70 measured with LDH-1 for control and SK-treated patients, respectively, which are indeed similar to the results of the present study.

Another advantage of calculation of infarct size from HBDH rather than from CK values is that HBDH-infarct size can be incorporated easily and routinely in trials on infarct size limitation as serum HBDH has to measured only twice a day during the first 2 days and once a day during the following 3 days at low cost. No assumption regarding the HBDH release function (ff[t]) is incorporated in the calculation. Thus factors which increase (e.g., SK) or decrease (e.g., beta blockers) the HBDH release rate do not influence any parameter involved in the calculation. The quantity of the release as well as the rate at which HBDH is released are the outcome of the calculation, and can be used in rapidly releasing infarcts (reperfusion) as well as in slowly releasing infarcts (unreperfused infarcts) (see also reference 22).

The enzymatic method for quantitating myocardial infarct size has one major drawback since patients must survive the first 3 days to enable calculation of cumulative enzyme release. In order to prevent bias resulting from the higher mortality rate among patients in the control group, we included the patients who died early from extensive infarctions giving those a large value for HBDHQ72. Since this value was chosen arbitrarily nonparametric statistical tests were used. Similarly, patients without infarction were included with a low value for HBDHQ72 (40 U/L).

Enzyme washout, as expressed as the HBDHQ4/HBDHQ72 release ratio, was increased in all groups of patients after thrombolytic therapy. The latter finding is not completely understood. Shell et al.\textsuperscript{40} demonstrated that reperfusion of the infarcted myocardium significantly augments the release rate of CK-MB, while Ong et al.\textsuperscript{41} reported that in patients with AMI not treated with thrombolytic agents a rapid release rate of CK-MB correlated with improvement of global left ventricular function and regional left ventricular wall motion. These reports suggest that a rapid enzyme release rate is a manifestation of recanalization, either spontaneous or
induced by thrombolytic therapy. Accordingly several authors advocated the use of the time to peak CK (or CK-MB) as a noninvasive in vitro index to determine the success of reperfusion.10-13 However, the present study indicates that one should be very cautious about interpreting a rapid enzyme release rate to be a manifestation of thrombolysis-induced recanalization, since the median rate of HBDH release in the patients with unsuccessful SK treatment (0.59) was significantly (p < 0.02) higher than that in conventionally treated (control) patients (0.48) (Fig. 2). One can speculate on other effects of SK in infarcted hearts besides its thrombolytic action. Fung and Rabin,42 who subjected rabbit hearts to ischemia (low-flow perfusion) plus anoxia (perfusate equilibrated with 95% nitrogen + 5% carbon dioxide), found that continuous administration of SK before reperfusion and during reperfusion resulted in a greater recovery of ventricular function than reperfusion alone. Puckett et al.43 demonstrated a vasodilatory effect of SK in the nonischemic, isolated rat heart. Furthermore, these authors found less enzyme release during reperfusion of the globally ischemic isolated rat heart in the presence of SK compared to the control ischemic rat heart, suggesting that SK offers an overall protective effect from the damage normally incurred during ischemia.

The present study supports the concept that early thrombolysis will limit infarct size. In fact, the greatest limitation of infarct size determined from HBDH release was observed in patients treated within 2 hours (37%), whereas the effect of thrombolytic therapy was smaller in those treated between 2 and 4 hours (13%). The limitation of infarct size was definitely related to the results of reperfusion (Fig. 2) and to preservation of global and regional left ventricular function as well as to the survival rate.7 Further studies should compare the relative value of various interventions to establish reperfusion, including intravenous SK, rt-PA or acetylated SK-plasminogen complex, intracoronary administration of these compounds, and immediate percutaneous transluminal coronary angioplasty. Determination of infarct size by means of the methods in the present study will aid in the comparison of such interventions in addition to measurement of left ventricular function and survival.

REFERENCES


